Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pravastatin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR known ✓ | P04035 | 9/20 | 1.00 |
| ▸ | SLCO1B1 | Q9Y6L6 | 4/20 | 1.00 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 1.00 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.84 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.71 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.71 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.55 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.55 |
| ▸ | PGR | P06401 | 1/20 | 0.55 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pravastatin SCHEMBL1683285 | 1.00 | HMGCR (1.00) | HMGCRSLCO1B1SLC22A8SLCO1B3ALOX15 | |
| Pravastatin SCHEMBL13743095 | 1.00 | HMGCR (1.00) | HMGCRSLCO1B1SLC22A8SLCO1B3ALOX15 | |
| Pravastatin SCHEMBL5580577 | 1.00 | HMGCR (1.00) | HMGCRSLCO1B1SLC22A8SLCO1B3ALOX15 | |
| Pravastatin SCHEMBL14627881 | 1.00 | HMGCR (1.00) | HMGCRSLCO1B1SLC22A8SLCO1B3ALOX15 | |
| Pravastatin SCHEMBL15091182 | 1.00 | HMGCR (1.00) | HMGCRSLCO1B1SLC22A8SLCO1B3ALOX15 | |
| Pravastatin SCHEMBL19993736 | 1.00 | HMGCR (1.00) | HMGCRSLCO1B1SLC22A8SLCO1B3ALOX15 | |
| Pravastatin SCHEMBL23936980 | 1.00 | HMGCR (1.00) | HMGCRSLCO1B1SLC22A8SLCO1B3ALOX15 | |
| Pravastatin SCHEMBL183608 | 1.00 | HMGCR (1.00) | HMGCRSLCO1B1SLC22A8SLCO1B3ALOX15 | |
| Pravastatin SCHEMBL12567266 | 1.00 | HMGCR (1.00) | HMGCRSLCO1B1SLC22A8SLCO1B3ALOX15 | |
| Pravastatin SCHEMBL14621551 | 1.00 | HMGCR (1.00) | HMGCRSLCO1B1SLC22A8SLCO1B3ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4566597-A1 | STATINS USEFUL IN THE TREATMENT OF SPLACHNIC VASCULAR DYSFUNCTIONS | Hospital Clínic de Barcelona (ES) | 2025-06-11 | — | — | EP | disclosed |
| US-9345671-B2 | Adiponectin production enhancer | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-05-24 | — | — | US | disclosed |
| US-20160058751-A1 | COMPOSITION AND METHOD FOR TREATING CANCER | CELLWORKS GROUP, INC. (US) | 2016-03-03 | — | — | US | disclosed |
| EP-2512514-B1 | SCREENING METHOD FOR IDENTIFYING COMPOUNDS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS | UNIV KYOTO (JP) | 2014-11-05 | — | — | EP | disclosed |
| US-8637274-B2 | Inhibitor for the formation of gamma-secretase complex | KOWA COMPANY, LTD. (JP) | 2014-01-28 | — | — | US | disclosed |
| US-20130210860-A1 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT AGAINST LYMPHEDEMA | KOWA CO., LTD. (JP) | 2013-08-15 | — | — | US | disclosed |
| EP-2626069-A1 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT AGAINST LYMPHEDEMA | The University of Tokyo (JP) | 2013-08-14 | — | — | EP | disclosed |
| EP-1621210-B1 | ADIPONECTIN PRODUCTION ENHANCER | DAIICHI SANKYO CO LTD (JP) | 2013-06-19 | — | — | EP | disclosed |
| US-20130115622-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | KYOTO UNIVERSITY (JP) | 2013-05-09 | — | — | US | disclosed |
| EP-1782804-B1 | MEDICINAL COMPOSITION, COMPRISING A HMG-CoA REDUCTASE INHIBITOR AND AN AMINO ALCOHOL DERIVATIVE, AS IMMUNOSUPPRESSANT | DAIICHI SANKYO CO LTD (JP) | 2011-12-28 | — | — | EP | disclosed |
| US-20060247299-A1 | Sugar intake-ability enhancer | SANKYO COMPANY, LIMITED (JP) | 2006-11-02 | — | — | US | disclosed |
| EP-1702626-A1 | INHIBITOR FOR THE FORMATION OF GAMMAD-SECRETASE COMPLEX | Kowa Company Ltd. (JP) | 2006-09-20 | — | — | EP | disclosed |
| US-6998422-B2 | Lipid peroxide-lowering compositions | SANKYO COMPANY, LIMITED (JP) | 2006-02-14 | — | — | US | disclosed |
| EP-1621210-A1 | ADIPONECTIN PRODUCTION ENHANCER | Sankyo Company, Limited (JP) | 2006-02-01 | — | — | EP | disclosed |
| EP-1618893-A1 | SUGAR INTAKE-ABILITY ENHANCER | Sankyo Company, Limited (JP) | 2006-01-25 | — | — | EP | disclosed |
| US-20050059720-A1 | Medicinal compositions for the prevention or treatment of cardiac failure | SANKYO COMPANY, LIMITED (JP) | 2005-03-17 | — | — | US | disclosed |
| US-20030229124-A1 | Lipid peroxide-lowering compositions | SANKYO COMPANY, LIMITED (JP) | 2003-12-11 | — | — | US | disclosed |
| US-20030195167-A1 | PTX3-gene expression inhibitor | KOWA CO., LTD. (JP) | 2003-10-16 | — | — | US | disclosed |
| US-20030181500-A1 | Medicinal compositions for the prevention or treatment of cardiac failure | SANKYO COMPANY, LIMITED (JP) | 2003-09-25 | — | — | US | disclosed |
| US-5491167-A | INHIBITORS OF CHOLESTEROL BIOSYNTHESIS | SANKYO COMPANY, LIMITED (JP) | 1996-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229124-A1 | Lipid peroxide-lowering compositions | PHOSPHO1, PPIP5K2, GPX4 | HMGCR 28/4885SLCO1B1 1623/4885SLC22A8 1002/4885 |
| US-20050059720-A1 | Medicinal compositions for the prevention or treatment of cardiac failure | HMGCR, AGTR2, ACE | HMGCR 1/4885SLCO1B1 579/4885SLC22A8 297/4885 |
| US-20160058751-A1 | COMPOSITION AND METHOD FOR TREATING CANCER | KRAS, NRAS, TP53 | HMGCR 1190/4885SLCO1B1 4018/4885SLC22A8 4232/4885 |
| US-20130210860-A1 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT AGAINST LYMPHEDEMA | LTA, PON1, LPO | HMGCR 383/4885SLCO1B1 3660/4885SLC22A8 2348/4885 |
| US-20060247299-A1 | Sugar intake-ability enhancer | SLC2A1, SLC2A3, SLC2A4 | HMGCR 15/4885SLCO1B1 739/4885SLC22A8 572/4885 |
| US-20030195167-A1 | PTX3-gene expression inhibitor | CCR3, CFH, SERPINH1 | HMGCR 1909/4885SLCO1B1 2271/4885SLC22A8 2013/4885 |
| US-20030181500-A1 | Medicinal compositions for the prevention or treatment of cardiac failure | HMGCR, AGTR2, ACE | HMGCR 1/4885SLCO1B1 579/4885SLC22A8 297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.